Ingigerdur Sverrisdottir
Overview
Explore the profile of Ingigerdur Sverrisdottir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rognvaldsson S, Gasparini A, Thorsteinsdottir S, Sverrisdottir I, Eythorsson E, Long T, et al.
Br J Haematol
. 2024 Dec;
206(3):899-906.
PMID: 39721598
Monoclonal gammopathy of undetermined significance (MGUS) is the asymptomatic precursor of multiple myeloma and related diseases but has also been associated with thrombosis. Prior studies have not been based on...
2.
Blimark C, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, et al.
Haematologica
. 2024 Jul;
110(1):163-172.
PMID: 39021214
In multiple myeloma (MM), advancements in treatments and toxicity management have enhanced survival rates. This, coupled with shifting age demographics in MM, necessitates an updated assessment of infection risks in...
3.
Einarsdottir S, Sverrisdottir I, Villegas-Scivetti M, Day C, Turesson I, Juliusson G, et al.
Haematologica
. 2024 Jun;
110(1):179-182.
PMID: 38934063
No abstract available.
4.
Sverrisdottir I, Thorsteinsdottir S, Rognvaldsson S, Aspelund T, Vidarsson B, Onundarson P, et al.
Ann Intern Med
. 2024 May;
177(6):711-718.
PMID: 38768457
Background: Monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and related conditions. In previous registry-based, retrospective studies, autoimmune diseases have been associated with MGUS. However,...
5.
Rognvaldsson S, Thorsteinsdottir S, Syriopoulou E, Sverrisdottir I, Turesson I, Eythorsson E, et al.
Haematologica
. 2024 Jan;
109(7):2250-2255.
PMID: 38205512
There is some evidence that a prior cancer is a risk factor for the development of multiple myeloma (MM). If this is true, prior cancer should be associated with a...
6.
Sigurbergsdottir A, Rognvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Sigurdardottir G, Vidarsson B, et al.
Haematologica
. 2023 Jul;
108(12):3392-3398.
PMID: 37439374
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor condition that precedes multiple myeloma and related disorders but has also been associated with other medical conditions. Since systematic screening...
7.
Einarsdottir S, Sverrisdottir I, Vaht K, Bergstrom T, Brune M, Andersson P, et al.
Transplant Cell Ther
. 2023 Jan;
29(4):275.e1-275.e5.
PMID: 36720458
Revaccination against tetanus and diphtheria after allogeneic hematopoietic stem cell transplantation (HCT) is usually effective, but the duration of the immunity is unknown. We conducted this study to evaluate humoral...
8.
Moore K, Turesson I, Genell A, Klausen T, Knut-Bojanowska D, Redder L, et al.
Haematologica
. 2022 Oct;
108(6):1640-1651.
PMID: 36300775
The prevalence of multiple myeloma (MM) is increasing in Nordic countries and the rest of the western world. Patients aged ≥75 years at diagnosis constitute an increasing proportion of all...
9.
Thorsteinsdottir S, Gislason G, Aspelund T, Sverrisdottir I, Landgren O, Turesson I, et al.
Haematologica
. 2019 Dec;
105(4):1067-1073.
PMID: 31792034
Multiple myeloma causes lytic bone lesions and fractures. The impact of fractures on multiple myeloma (MM) survival is unclear. The aim of this study was to evaluate the effect of...